Biologics major cost driver in IBD management in the US

Biologics major cost driver in IBD management in the US PharmacoEconomics & Outcomes News 792, p7 - 2 Dec 2017 Biologics major cost driver in IBD management in the US The increasing use of biologic therapies for the treatment of inflammatory bowel disease (IBD) has a major cost impact in the US, according to researchers from Stanford University School of Medicine, US. The researchers used data from the Truven Marketscan database to assess outpatient drug use trends of IBD medications over a 9-year period (2007–2015) and associated costs. The market share of biologics relative to other IBD medications, including immunomodulators, 5-aminosalicylic-acids (5-ASAs) and oral corticosteroids, was also determined. The analysis of data for 415 405 patients with IBD showed that the proportion of patients using biologics increased nearly threefold, from 7.1% in 2007 to 20.5% in 2015. Consequently, there was a consistent rise in the market share of biologics (from 13.7% to 30.1%) and fall for both immunomodulators and 5-ASAs (from 22.7% to 16.0% and 48.6% to 39.2%, respectively). Corticosteroid-only use remained stable at approximately 15%. The per-member per-year (PMPY) costs of an average patient receiving biologic therapy increased from $US25 275 in 2007 to $36 051 in 2015, and the share of PMPY costs for biologics increased from 72.9% to 85.7%. The study also showed that the share of PMPY costs for biologics was even higher in paediatric patients with IBD (increasing from 81.7% to 94.9%). Yu H, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Alimentary Pharmacology and Therapeutics : 22 Nov 2017. Available from: URL: http://doi.org/10.1111/apt.14430 803286173 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Biologics major cost driver in IBD management in the US

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/biologics-major-cost-driver-in-ibd-management-in-the-us-gcGcHTVwZf
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4530-6
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p7 - 2 Dec 2017 Biologics major cost driver in IBD management in the US The increasing use of biologic therapies for the treatment of inflammatory bowel disease (IBD) has a major cost impact in the US, according to researchers from Stanford University School of Medicine, US. The researchers used data from the Truven Marketscan database to assess outpatient drug use trends of IBD medications over a 9-year period (2007–2015) and associated costs. The market share of biologics relative to other IBD medications, including immunomodulators, 5-aminosalicylic-acids (5-ASAs) and oral corticosteroids, was also determined. The analysis of data for 415 405 patients with IBD showed that the proportion of patients using biologics increased nearly threefold, from 7.1% in 2007 to 20.5% in 2015. Consequently, there was a consistent rise in the market share of biologics (from 13.7% to 30.1%) and fall for both immunomodulators and 5-ASAs (from 22.7% to 16.0% and 48.6% to 39.2%, respectively). Corticosteroid-only use remained stable at approximately 15%. The per-member per-year (PMPY) costs of an average patient receiving biologic therapy increased from $US25 275 in 2007 to $36 051 in 2015, and the share of PMPY costs for biologics increased from 72.9% to 85.7%. The study also showed that the share of PMPY costs for biologics was even higher in paediatric patients with IBD (increasing from 81.7% to 94.9%). Yu H, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Alimentary Pharmacology and Therapeutics : 22 Nov 2017. Available from: URL: http://doi.org/10.1111/apt.14430 803286173 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off